CorMedix Inc.(CRMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CRMD CorMedix Inc.

Closed 11-22 16:00:00 EST

9.96

-0.37

-3.58%

盘后9.94

-0.02-0.20%

19:46 EST

High10.37	Low9.93	Vol880.02K
Open10.34	D1 Closing10.33	Amplitude4.26%
Mkt Cap604.34M	Tradable Cap598.66M	Total Shares60.68M
T/O8.88M	T/O Rate1.46%	Tradable Shares60.11M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"CRMD","market":"US","secType":"STK","nameCN":"CorMedix Inc.","latestPrice":9.96,"timestamp":1732309200000,"preClose":10.33,"halted":0,"volume":880019,"hourTrading":{"tag":"盘后","latestPrice":9.94,"preClose":9.96,"latestTime":"19:46 EST","volume":17183,"amount":171011.4499,"timestamp":1732322818832},"delay":0,"floatShares":60106043,"shares":60677204,"eps":-0.797644,"marketStatus":"Closed","change":-0.37,"latestTime":"11-22 16:00:00 EST","open":10.34,"high":10.37,"low":9.93,"amount":8878640.173774,"amplitude":0.042594,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.797644,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1732525200000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1273723200000,"exchange":"NASDAQ","adjPreClose":10.33,"preHourTrading":{"tag":"盘前","latestPrice":10.43,"preClose":10.33,"latestTime":"08:51 EST","volume":7709,"amount":80130.1328035,"timestamp":1732283473111},"postHourTrading":{"tag":"盘后","latestPrice":9.94,"preClose":9.96,"latestTime":"19:46 EST","volume":17183,"amount":171011.4499,"timestamp":1732322818832},"volumeRatio":0.771917,"impliedVol":0.6782,"impliedVolPercentile":0.3254},"requestUrl":"/m/hq/s/CRMD/tweets","defaultTab":"tweets","newsList":[{"id":"2481174735","title":"New Strong Buy Stocks for November 8th","url":"https://stock-news.laohu8.com/highlight/detail?id=2481174735","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481174735?lang=en_us&edition=fundamental","pubTime":"2024-11-08 19:12","pubTimestamp":1731064320,"startTime":"0","endTime":"0","summary":"Here are five stocks added to the Zacks Rank #1  List today:. Sappi Limited SPPJY: This wood fiber-based renewable resources company has seen the Zacks Consensus Estimate for its current year earnings increasing 16.7% over the last 60 days.Flushing Financial Corporation FFIC: This bank holding company for Flushing Bank has seen the Zacks Consensus Estimate for its current year earnings increasing 5.6% over the last 60 days.Flushing Financial Corporation price-consensus-chart | Flushing Financial Corporation Quote. CorMedix Inc.CRMD: This biopharmaceutical company has seen the Zacks Consensus Estimate for its current year earnings increasing 20.7% over the last 60 days.NETGEAR, Inc. NTGR: This connectivity solutions provider has seen the Zacks Consensus Estimate for its current year earnings increasing 20.6% over the last 60 days.AAC Technologies Holdings Inc. AACAY: This investment holding company has seen the Zacks Consensus Estimate for its current year earnings increasing 11.1% over","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/rP1EV4y5.bnG6Q.bCrRgNA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/22d93c77b91a36ccc2d6a44613af467e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/rP1EV4y5.bnG6Q.bCrRgNA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/22d93c77b91a36ccc2d6a44613af467e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/strong-buy-stocks-november-8th-111200997.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","AACAY","CRMD","SPPJY","BK4020","BK4211","BK4145","NTGR","BK4199","FFIC"],"gpt_icon":0},{"id":"1178980738","title":"Stock Track | CorMedix Soars as Analysts Turn Bullish on Revenue and Earnings Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=1178980738","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178980738?lang=en_us&edition=fundamental","pubTime":"2024-11-04 23:10","pubTimestamp":1730733031,"startTime":"0","endTime":"0","summary":"Shares of CorMedix Inc.  surged 5.11% on Friday, November 4th, driven by heightened optimism from Wall Street analysts regarding the biopharmaceutical company's future growth prospects.According to the latest consensus estimates, analysts have significantly raised their revenue and earnings forecasts for CorMedix in 2025. They now anticipate the company to generate revenues of $111 million next year, reflecting a substantial increase from their previous estimate of $100 million. Additionally, th","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | CorMedix Soars as Analysts Turn Bullish on Revenue and Earnings Outlook","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["CRMD"],"gpt_icon":0},{"id":"2480894583","title":"CorMedix Inc. to Participate in the Truist Securities BioPharma Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2480894583","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480894583?lang=en_us&edition=fundamental","pubTime":"2024-11-04 21:30","pubTimestamp":1730727000,"startTime":"0","endTime":"0","summary":"BERKELEY HEIGHTS, N.J., Nov.  04, 2024  (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatenin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/04/2974080/0/en/CorMedix-Inc-to-Participate-in-the-Truist-Securities-BioPharma-Symposium.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CRMD"],"gpt_icon":0},{"id":"2480303415","title":"Rainbows and Unicorns: CorMedix Inc. (NASDAQ:CRMD) Analysts Just Became A Lot More Optimistic","url":"https://stock-news.laohu8.com/highlight/detail?id=2480303415","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480303415?lang=en_us&edition=fundamental","pubTime":"2024-11-04 18:37","pubTimestamp":1730716653,"startTime":"0","endTime":"0","summary":"CorMedix Inc.  shareholders will have a reason to smile today, with the analysts making substantial upgrades to next year's forecasts. The consensus statutory numbers for both revenue and earnings per share  increased, with their view clearly much more bullish on the company's business prospects.Following the upgrade, the current consensus from CorMedix's four analysts is for revenues of US$111m in 2025 which - if met - would reflect a sizeable increase on its sales over the past 12 months. The losses are expected to disappear over the next year or so, with forecasts for a profit of US$0.45 per share next year. Before this latest update, the analysts had been forecasting revenues of US$100m and earnings per share  of US$0.18 in 2025. So we can see there's been a pretty clear increase in analyst sentiment in recent times, with both revenues and earnings per share receiving a decent lift in the latest estimates.Another way to search for interesting companies that could be  reaching an in","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/TLyt5D16lsSwRjJRVjlUTA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/fd5474a7eee0c5f442903b68fe63249b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/TLyt5D16lsSwRjJRVjlUTA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/fd5474a7eee0c5f442903b68fe63249b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rainbows-unicorns-cormedix-inc-nasdaq-103733294.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","LU2210150020.SGD","IE00B3QW5Z07.USD","NDAQ","LU2095319765.USD","BK4007","BK4588","NQmain","CRMD",".IXIC","IE00BKPKM429.USD","QID","SQQQ","MNQmain","PSQ","LU2210149790.SGD","QLD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4112","TQQQ"],"gpt_icon":1},{"id":"2480388888","title":"While shareholders of CorMedix (NASDAQ:CRMD) are in the black over 1 year, those who bought a week ago aren't so fortunate","url":"https://stock-news.laohu8.com/highlight/detail?id=2480388888","media":"Simply Wall St.","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480388888?lang=en_us&edition=fundamental","pubTime":"2024-11-01 20:21","pubTimestamp":1730463702,"startTime":"0","endTime":"0","summary":"It's been a soft week for CorMedix Inc.  shares, which are down 23%. But that doesn't detract from the splendid returns of the last year. Like an eagle, the share price soared 188% in that time. So some might not be surprised to see the price retrace some. The real question is whether the business is trending in the right direction.In light of the stock dropping 23% in the past week, we want to investigate the longer term story, and see if fundamentals have been the driver of the company's positive one-year return.In the last year CorMedix saw its revenue grow by 41,184%. That's well above most other pre-profit companies. And the share price has responded, gaining 188% as we previously mentioned. That sort of revenue growth is bound to attract attention, even if the company doesn't turn a profit. The strong share price rise indicates optimism, so there may be a better opportunity for buyers as the hype fades a bit.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/TLyt5D16lsSwRjJRVjlUTA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/fd5474a7eee0c5f442903b68fe63249b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/TLyt5D16lsSwRjJRVjlUTA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/fd5474a7eee0c5f442903b68fe63249b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/while-shareholders-cormedix-nasdaq-crmd-122142426.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BGHQF748.EUR","CRMD",".IXIC","NDAQ","PSQ","BK4585","BK4007","QLD","LU2210150020.SGD","BK4112","IE00B3QW5Z07.USD","LU2210149790.SGD","LU2095319765.USD","SQQQ","IE00B64PRP62.GBP","TQQQ","BK4588","NQmain","IE00BKPKM429.USD","QID","MNQmain"],"gpt_icon":1},{"id":"2479870316","title":"CorMedix Is Maintained at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2479870316","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479870316?lang=en_us&edition=fundamental","pubTime":"2024-10-31 18:21","pubTimestamp":1730370060,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRMD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 31, 2024 06:21 ET (10:21 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRMD"],"gpt_icon":0},{"id":"2479786307","title":"CorMedix Inc : RBC Raises Target Price to $11 From $9","url":"https://stock-news.laohu8.com/highlight/detail?id=2479786307","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479786307?lang=en_us&edition=fundamental","pubTime":"2024-10-31 16:01","pubTimestamp":1730361678,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241031:nFWN3M7058:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CRMD"],"gpt_icon":0},{"id":"2479372280","title":"Cormedix Inc (CRMD) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Rising Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2479372280","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479372280?lang=en_us&edition=fundamental","pubTime":"2024-10-31 15:07","pubTimestamp":1730358421,"startTime":"0","endTime":"0","summary":"Net Revenue: $11.5 million for the third quarter of 2024.Net Loss: Approximately $2.8 million or 5 per share for Q3 2024.Operating Expenses: Increased 33% to $14.1 million in Q3 2024.Selling and Marketing Expense: Increased 66% to $6.7 million in Q3 2024.General and Administrative Expense: Increased 76% to $6.6 million in Q3 2024.R&D Expense: Decreased 73% to $0.7 million in Q3 2024.Cash and Cash Equivalents: $46 million as of September 30, 2024.Net Cash Used in Operations: $45 million for the nine months ended September 30, 2024.ATM Issuance Proceeds: Approximately $12.4 million in Q3 2024.GuruFocus has detected 4 Warning Signs with CRMD.For the complete transcript of the earnings call, please refer to the full earnings call transcript.The company has secured new agreements with two midsized dialysis operators and one large-scale operator, expanding access to 60% of US dialysis clinics.Cormedix Inc  expects to achieve positive EBITDA in the fourth quarter, indicating strong financial ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cormedix-inc-crmd-q3-2024-070701807.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CRMD"],"gpt_icon":0},{"id":"2479741534","title":"CorMedix Inc. Reports Q3 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2479741534","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479741534?lang=en_us&edition=fundamental","pubTime":"2024-10-31 12:52","pubTimestamp":1730350324,"startTime":"0","endTime":"0","summary":"Cormedix Inc. ( ($CRMD) ) has realeased its Q3 earnings. Here is a breakdown of the information Cormedix Inc. presented to its investors. CorMedix ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cormedix-inc-reports-q3-2024-financial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cormedix-inc-reports-q3-2024-financial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CRMD"],"gpt_icon":0},{"id":"2479106027","title":"CorMedix (CRMD) Q3 2024 Earnings Call Transcript","url":"https://stock-news.laohu8.com/highlight/detail?id=2479106027","media":"Motley Fool Transcribing","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479106027?lang=en_us&edition=fundamental","pubTime":"2024-10-31 11:00","pubTimestamp":1730343618,"startTime":"0","endTime":"0","summary":"CRMD earnings call for the period ending September 30, 2024.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com/earnings/call-transcripts/2024/10/30/cormedix-crmd-q3-2024-earnings-call-transcript/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_motley_transcript","symbols":["CRMD"],"gpt_icon":0},{"id":"2479078728","title":"CorMedix Inc reports results for the quarter ended in January 1 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2479078728","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479078728?lang=en_us&edition=fundamental","pubTime":"2024-10-30 23:13","pubTimestamp":1730301190,"startTime":"0","endTime":"0","summary":"* CorMedix Inc    reported a quarterly adjusted loss of 5 cents per share for the quarter ended January 1, higher than the same quarter last year, when the company reported EPS of -17 cents.  The mean","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRMD"],"gpt_icon":0},{"id":"1152540205","title":"Stock Track | CorMedix Plunges Over 12% as Commercialization Concerns Overshadow Q3 Beat","url":"https://stock-news.laohu8.com/highlight/detail?id=1152540205","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152540205?lang=en_us&edition=fundamental","pubTime":"2024-10-30 21:35","pubTimestamp":1730295348,"startTime":"0","endTime":"0","summary":"Shares of CorMedix Inc.  plummeted over 12% on October 30, 2024, despite the biopharmaceutical company reporting better-than-expected third-quarter results. The stock's decline appears to be driven by concerns surrounding the commercialization of its lead product, DefenCath, and the company's ability to fund operations beyond the near term.For the third quarter of 2024, CorMedix reported net revenue of $11.5 million, largely driven by successful implementation by an initial anchor customer, a mi","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["CRMD"],"gpt_icon":0},{"id":"2479678976","title":"CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2479678976","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479678976?lang=en_us&edition=fundamental","pubTime":"2024-10-30 20:40","pubTimestamp":1730292007,"startTime":"0","endTime":"0","summary":"CorMedix  came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.17 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 50%. A quarter ago, it was expected that this pharmaceutical and medical device company would post a loss of $0.26 per share when it actually produced a loss of $0.25, delivering a surprise of 3.85%.Over the last four quarters, the company has surpassed consensus EPS estimates three times.CorMedix , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $11.46 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 4.15%. This compares to zero revenues a year ago.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Tw87WEC1wh0JNb8.IBuFMA--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/03fca48475577988aa4e0db94f484b4e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Tw87WEC1wh0JNb8.IBuFMA--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/03fca48475577988aa4e0db94f484b4e"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cormedix-crmd-reports-q3-loss-124007547.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BEAM","CRMD"],"gpt_icon":0},{"id":"1153082992","title":"Stock Track | CorMedix Plunges Despite Q3 Beat on Commercialization Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=1153082992","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153082992?lang=en_us&edition=fundamental","pubTime":"2024-10-30 20:20","pubTimestamp":1730290827,"startTime":"0","endTime":"0","summary":"Shares of CorMedix Inc.  plummeted over 6% in pre-market trading on Tuesday, despite the biopharmaceutical company reporting better-than-expected third-quarter results. The stock's decline appears to be driven by concerns surrounding the commercialization of its lead product, DefenCath.While CorMedix reported its first full quarter of DefenCath sales, generating $11.5 million in revenue, the pace of commercialization appears to be slower than anticipated. The company noted that it has secured co","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["CRMD"],"gpt_icon":0},{"id":"2479203449","title":"Cormedix Q3 2024 GAAP EPS $(0.05) Beats $(0.14) Estimate, Sales $11.456M Beat $10.839M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2479203449","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479203449?lang=en_us&edition=fundamental","pubTime":"2024-10-30 19:33","pubTimestamp":1730288019,"startTime":"0","endTime":"0","summary":"Cormedix (NASDAQ:CRMD) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.14) by 64.29 percent. The company reported quarterly sales of $11.456 million which beat the analyst","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/10/41621751/cormedix-q3-2024-gaap-eps-0-05-beats-0-14-estimate-sales-11-456m-beat-10-839m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Cormedix Q3 2024 GAAP EPS $(0.05) Beats $(0.14) Estimate, Sales $11.456M Beat $10.839M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRMD"],"gpt_icon":0},{"id":"2479203946","title":"CorMedix Q3 Basic EPS USD -0.05","url":"https://stock-news.laohu8.com/highlight/detail?id=2479203946","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479203946?lang=en_us&edition=fundamental","pubTime":"2024-10-30 19:30","pubTimestamp":1730287803,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241030:nPLXC23FEA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CRMD"],"gpt_icon":0},{"id":"2479205319","title":"CorMedix Inc. Reports Third Quarter and Nine Month 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2479205319","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479205319?lang=en_us&edition=fundamental","pubTime":"2024-10-30 19:30","pubTimestamp":1730287800,"startTime":"0","endTime":"0","summary":" Q3 2024 Net Revenue of $11.5 million   Commercializing DefenCath with Four of Top Five US Dialysis Providers   Conference Call Scheduled for Today at 8:30 a.m. Eastern Time  BERKELEY HEIGHTS, N.J., O","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/30/2971591/0/en/CorMedix-Inc-Reports-Third-Quarter-and-Nine-Month-2024-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CRMD"],"gpt_icon":0},{"id":"2479899456","title":"CorMedix 2.0: New Leadership, New Approval, New Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2479899456","media":"seekingalpha","labels":["analysis"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479899456?lang=en_us&edition=fundamental","pubTime":"2024-10-29 01:33","pubTimestamp":1730136823,"startTime":"0","endTime":"0","summary":"CorMedix is a biopharmaceutical company that has undergone a re-birth as it enters a new phase with FDA approval of its anti-infective catheter solution, DefenCath.The company has faced challenges in ","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1087673356/image_1087673356.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1087673356/image_1087673356.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4730145-cormedix-2-0-new-leadership-new-approval-new-focus","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"analysis","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4007","CRMD"],"gpt_icon":0},{"id":"2478488709","title":"CorMedix Inc    expected to post a loss of 10 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2478488709","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478488709?lang=en_us&edition=fundamental","pubTime":"2024-10-28 21:02","pubTimestamp":1730120530,"startTime":"0","endTime":"0","summary":"* CorMedix Inc     is expected to show a rise in quarterly revenue when it reports  results on October 30 for the period ending September 30 2024   * The Berkeley Heights New Jersey-based  company is ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"CorMedix Inc    expected to post a loss of 10 cents a share - Earnings Preview","news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRMD"],"gpt_icon":0},{"id":"2478148494","title":"Cormedix (CRMD) Receives a Buy from Truist Financial","url":"https://stock-news.laohu8.com/highlight/detail?id=2478148494","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478148494?lang=en_us&edition=fundamental","pubTime":"2024-10-28 10:25","pubTimestamp":1730082310,"startTime":"0","endTime":"0","summary":"In a report released on October 25, Les Sulewski from Truist Financial maintained a Buy rating on Cormedix (CRMD – Research Report), with a price t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cormedix-crmd-receives-a-buy-from-truist-financial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cormedix-crmd-receives-a-buy-from-truist-financial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CRMD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cormedix.com","stockEarnings":[{"period":"1week","weight":-0.0609},{"period":"1month","weight":-0.142},{"period":"3month","weight":0.8283},{"period":"6month","weight":1.0176},{"period":"1year","weight":1.8224},{"period":"ytd","weight":1.7473}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.249}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.642857,"avgChangeRate":0.156968},{"month":2,"riseRate":0.5,"avgChangeRate":0.081232},{"month":3,"riseRate":0.571429,"avgChangeRate":0.079611},{"month":4,"riseRate":0.428571,"avgChangeRate":-0.050014},{"month":5,"riseRate":0.142857,"avgChangeRate":-0.15479},{"month":6,"riseRate":0.533333,"avgChangeRate":0.055667},{"month":7,"riseRate":0.466667,"avgChangeRate":0.062594},{"month":8,"riseRate":0.533333,"avgChangeRate":0.009001},{"month":9,"riseRate":0.4,"avgChangeRate":0.043586},{"month":10,"riseRate":0.466667,"avgChangeRate":0.048734},{"month":11,"riseRate":0.533333,"avgChangeRate":0.060954},{"month":12,"riseRate":0.428571,"avgChangeRate":0.065583}],"exchange":"NASDAQ","name":"CorMedix Inc.","nameEN":"CorMedix Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CorMedix Inc.(CRMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CorMedix Inc.(CRMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CorMedix Inc.,CRMD,CorMedix Inc.股票,CorMedix Inc.股票老虎,CorMedix Inc.股票老虎国际,CorMedix Inc.行情,CorMedix Inc.股票行情,CorMedix Inc.股价,CorMedix Inc.股市,CorMedix Inc.股票价格,CorMedix Inc.股票交易,CorMedix Inc.股票购买,CorMedix Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CorMedix Inc.(CRMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CorMedix Inc.(CRMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction